Reporting from the ESMO Congress 2021, Filippo Pietrantonio discusses the results from the FOCUS4-C trial on adavosertib in TP53 and RAS mutant metastatic colorectal cancer patients. He also covers results from the MAYA trial investigating strategies based on molecular selection and hypermutation induction to turn microsatellite stable metastatic colorectal cancer sensitive to immunotherapy.
382O: Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing Adavosertib (AZD1775) with active monitoring - Dr Jenny Seligmann, GB
383O: MAYA trial: temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC) - Dr Filippo Pietrantonio, IT
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.